US Stock Insider Trading | IDEAYA Biosciences Disclosed 1 Company Insider Trading on March 2

K-LinePoet · 2026-03-13T02:01:33+00:00

On March 2, 2026, Stein Jeffrey, director of IDEAYA Biosciences, purchased 50,000 shares with a total transaction amount of $1.6479 million. IDEAYA is a precision medicine company focused on oncology, dedicated to developing targeted therapies to improve patient treatment outcomes.

K-LinePoet

2026-03-13 02:01:33

Abstract generation in progress

On March 2, 2026, IDEAYA Biosciences (IDYA) disclosed a company insider trade. Director Stein Jeffrey purchased 50,000 shares.

[Recent Insider Trades]

Disclosure Date	Position	Name	Trade Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
March 2, 2026	Director	Stein Jeffrey	March 2, 2026	Buy	50,000	32.96	1,647,900
February 2, 2026	Executive	Ruiz Briseno Andres	November 28, 2025	Buy	1,253	16.91	21,200
February 2, 2026	Executive	Ruiz Briseno Andres	November 29, 2024	Buy	682	23.26	15,900
February 2, 2026	Executive	Snyder Douglas B.	November 28, 2025	Buy	2,080	16.91	35,200
February 19, 2025	Director	Hata Yujiro S	February 18, 2025	Buy	12,800	19.52	250,000
June 27, 2024	Executive	Throne Jason	June 27, 2024	Buy	47,100	7.01	329,900
June 27, 2024	Executive	Throne Jason	June 27, 2024	Buy	6,424	13.34	85,700
May 31, 2024	Executive	WHITE MICHAEL ANTHONY	May 29, 2024	Sell	27,600	36.23	1,001,600
May 31, 2024	Executive	WHITE MICHAEL ANTHONY	May 29, 2024	Buy	28,500	12.86	366,500
May 31, 2024	Executive	WHITE MICHAEL ANTHONY	May 29, 2024	Sell	851	36.78	31,300

[Company Profile]

IDEAYA Biosciences, Inc., headquartered in South San Francisco, California, was incorporated in Delaware in June 2015. The company is a precision medicine firm focused on oncology, dedicated to discovering and developing targeted therapies for patient populations selected through molecular diagnostics. Their approach combines broad capabilities in identifying and validating translational biomarkers with small molecule drug discovery to select patients most likely to benefit from their targeted therapies under development. They are applying these capabilities across various precision medicine areas, including direct targeting of oncogenic pathways and synthetic lethality, representing an emerging class of precision medicine targets.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.